Therapeutic role of Glycyrrhiza Uralensis fisher on benign prostatic hyperplasia through 5 alpha reductase regulation and apoptosis
- 31 July 2022
- journal article
- research article
- Published by Elsevier in Phytomedicine
- Vol. 105, 154371
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Science, ICT and Future Planning
- National Research Foundation of Korea (NRF-2018R1A2A3075684, NRF-2021R1A2C1012532, NRF-2021R1A2C2010460)
This publication has 30 references indexed in Scilit:
- Androgens and estrogens in benign prostatic hyperplasia: Past, present and futureDifferentiation, 2011
- Benign Prostatic HyperplasiaClinics in Geriatric Medicine, 2010
- Current status of 5α-reductase inhibitors in the management of lower urinary tract symptoms and BPHWorld Journal of Urology, 2009
- Pathology of benign prostatic hyperplasiaInternational Journal Of Impotence Research, 2008
- Chemistry and Structural Biology of Androgen ReceptorChemical Reviews, 2005
- SERENOA REPENS TREATMENT MODIFIES BAX/BCL-2 INDEX EXPRESSION AND CASPASE-3 ACTIVITY IN PROSTATIC TISSUE FROM PATIENTS WITH BENIGN PROSTATIC HYPERPLASIAJournal of Urology, 2005
- DIHYDROTESTOSTERONE AND THE PROSTATE: THE SCIENTIFIC RATIONALE FOR 5α-REDUCTASE INHIBITORS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIAJournal of Urology, 2004
- AUA Guideline on Management of Benign Prostatic Hyperplasia (2003). Chapter 1: Diagnosis and Treatment RecommendationsJournal of Urology, 2003
- The Bcl2 family: regulators of the cellular life-or-death switchNature Reviews Cancer, 2002
- Etiology and disease process of benign prostatic hyperplasiaThe Prostate, 1989